guanfacine ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antihypertensives, guanidine derivatives 1343 29110-47-2

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • guanfacine
  • guanfacine hydrochloride
  • guanfacine HCl
  • guanfacine monohydrochloride
A centrally acting antihypertensive agent with specificity towards ADRENERGIC ALPHA-2 RECEPTORS.
  • Molecular weight: 246.09
  • Formula: C9H9Cl2N3O
  • CLOGP: 1.37
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 3
  • TPSA: 78.97
  • ALOGS: -3.25
  • ROTB: 2

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
3 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 1 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 50 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.35 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 81 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 5.60 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 4.50 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.28 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 15 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Oct. 27, 1986 FDA PROMIUS PHARMA
March 30, 2017 PMDA Shionogi & Co., Ltd.

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Product substitution issue 126.72 26.41 39 2014 14018 50589053
Aggression 81.33 26.41 31 2022 21085 50581986
Somnolence 62.54 26.41 51 2002 154934 50448137
Abnormal behaviour 51.89 26.41 22 2031 19636 50583435
Impulsive behaviour 51.85 26.41 12 2041 1446 50601625
Intentional overdose 49.34 26.41 31 2022 62473 50540598
Psychomotor hyperactivity 44.39 26.41 16 2037 9285 50593786
Suicidal ideation 42.53 26.41 27 2026 55358 50547713
Product administered to patient of inappropriate age 40.13 26.41 11 2042 2619 50600452
Bradycardia 36.48 26.41 26 2027 64400 50538671
Atrioventricular dissociation 32.92 26.41 6 2047 220 50602851
Irritability 32.68 26.41 18 2035 28408 50574663
Educational problem 29.82 26.41 6 2047 373 50602698
Sinus arrhythmia 26.92 26.41 7 2046 1362 50601709

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Product substitution issue 354.58 31.33 105 4255 9067 29561100
Aggression 246.83 31.33 115 4245 35426 29534741
Agitation 121.64 31.33 82 4278 51222 29518945
Psychomotor hyperactivity 115.51 31.33 44 4316 8169 29561998
Abnormal behaviour 112.97 31.33 59 4301 23068 29547099
Irritability 101.06 31.33 54 4306 22098 29548069
Tic 93.05 31.33 26 4334 1809 29568358
Impulsive behaviour 87.08 31.33 25 4335 1918 29568249
Somnolence 80.01 31.33 83 4277 93872 29476295
Drug ineffective 79.19 31.33 168 4192 363002 29207165
Bradycardia 68.84 31.33 65 4295 65564 29504603
Anger 56.62 31.33 29 4331 10861 29559306
Educational problem 53.66 31.33 13 4347 514 29569653
Dystonia 50.79 31.33 26 4334 9723 29560444
Disturbance in attention 50.06 31.33 34 4326 21390 29548777
Brugada syndrome 49.97 31.33 13 4347 688 29569479
Insomnia 44.71 31.33 60 4300 88701 29481466
Negativism 42.05 31.33 10 4350 365 29569802
Product quality issue 41.41 31.33 27 4333 15868 29554299
Sinus bradycardia 41.16 31.33 24 4336 11579 29558588
Emotional disorder 40.53 31.33 18 4342 4913 29565254
Suicidal ideation 39.46 31.33 36 4324 34680 29535487
Attention deficit hyperactivity disorder 38.95 31.33 14 4346 2203 29567964
Affective disorder 37.73 31.33 15 4345 3111 29567056
Sinus arrest 36.59 31.33 12 4348 1435 29568732
Product administered to patient of inappropriate age 36.49 31.33 14 4346 2641 29567526
Defiant behaviour 36.18 31.33 5 4355 4 29570163
Anxiety 35.98 31.33 53 4307 85312 29484855
Hallucination 35.27 31.33 38 4322 44674 29525493
Disturbance in social behaviour 34.68 31.33 12 4348 1690 29568477
Drug dose titration not performed 34.65 31.33 8 4352 256 29569911
Autism spectrum disorder 32.60 31.33 12 4348 2020 29568147
Priapism 32.50 31.33 15 4345 4473 29565694

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Product substitution issue 389.67 24.47 116 5368 17745 64475503
Aggression 305.76 24.47 123 5361 46109 64447139
Psychomotor hyperactivity 140.48 24.47 51 5433 14400 64478848
Impulsive behaviour 131.73 24.47 33 5451 2630 64490618
Abnormal behaviour 122.75 24.47 59 5425 33563 64459685
Agitation 114.85 24.47 79 5405 88288 64404960
Irritability 111.91 24.47 57 5427 36689 64456559
Bradycardia 98.54 24.47 81 5403 118138 64375110
Tic 98.05 24.47 26 5458 2593 64490655
Somnolence 86.31 24.47 96 5388 203549 64289699
Educational problem 76.24 24.47 15 5469 389 64492859
Suicidal ideation 60.45 24.47 48 5436 66494 64426754
Anger 58.54 24.47 28 5456 15713 64477535
Intentional overdose 55.51 24.47 52 5432 89892 64403356
Brugada syndrome 51.52 24.47 13 5471 1065 64492183
Disturbance in attention 46.95 24.47 34 5450 41040 64452208
Sinus bradycardia 46.01 24.47 27 5457 22866 64470382
Electrocardiogram QT prolonged 45.33 24.47 44 5440 79404 64413844
Hypotension 44.40 24.47 99 5385 380875 64112373
Priapism 42.27 24.47 15 5469 3955 64489293
Dystonia 39.90 24.47 23 5461 18842 64474406
Mood swings 38.82 24.47 22 5462 17446 64475802
Autism spectrum disorder 38.37 24.47 10 5474 931 64492317
Defiant behaviour 37.09 24.47 5 5479 8 64493240
Product administered to patient of inappropriate age 36.49 24.47 14 5470 4587 64488661
Drug ineffective 36.36 24.47 154 5330 840093 63653155
Sedation 35.70 24.47 29 5455 41433 64451815
Attention deficit hyperactivity disorder 35.42 24.47 12 5472 2758 64490490
Disturbance in social behaviour 35.08 24.47 13 5471 3874 64489374
Affective disorder 34.91 24.47 15 5469 6565 64486683
Product quality issue 34.81 24.47 25 5459 29774 64463474
Sinus arrest 34.13 24.47 12 5472 3078 64490170
Overdose 32.93 24.47 53 5431 159513 64333735
Insomnia 32.02 24.47 59 5425 197777 64295471
Drug dose titration not performed 31.47 24.47 8 5476 675 64492573
Emotional disorder 31.08 24.47 17 5467 12590 64480658
Hallucination 30.18 24.47 34 5450 72754 64420494
Homicidal ideation 29.79 24.47 11 5473 3246 64490002
Hyperammonaemia 29.06 24.47 15 5469 9889 64483359
Tachycardia 28.59 24.47 48 5436 149531 64343717
Lethargy 26.90 24.47 32 5452 72562 64420686
Atrioventricular dissociation 26.31 24.47 6 5478 319 64492929

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC C02AC02 CARDIOVASCULAR SYSTEM
ANTIHYPERTENSIVES
ANTIADRENERGIC AGENTS, CENTRALLY ACTING
Imidazoline receptor agonists
FDA MoA N0000009918 Adrenergic alpha2-Agonists
FDA EPC N0000175554 Central alpha-2 Adrenergic Agonist
CHEBI has role CHEBI:176497 geroprotectors
MeSH PA D018663 Adrenergic Agents
MeSH PA D000322 Adrenergic Agonists
MeSH PA D058647 Adrenergic alpha-2 Receptor Agonists
MeSH PA D000316 Adrenergic alpha-Agonists
MeSH PA D000959 Antihypertensive Agents
MeSH PA D002317 Cardiovascular Agents
MeSH PA D018377 Neurotransmitter Agents

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Hypertensive disorder indication 38341003 DOID:10763
Attention deficit hyperactivity disorder indication 406506008
Constipation contraindication 14760008 DOID:2089
Myocardial infarction contraindication 22298006 DOID:5844
Alcohol intoxication contraindication 25702006
Orthostatic hypotension contraindication 28651003
Dehydration contraindication 34095006
Depressive disorder contraindication 35489007
Low blood pressure contraindication 45007003
End stage renal disease contraindication 46177005 DOID:784
Bradycardia contraindication 48867003
Cerebrovascular disease contraindication 62914000 DOID:6713
Heart block contraindication 233916004
Disease of liver contraindication 235856003 DOID:409
Syncope contraindication 271594007
Drowsy contraindication 271782001
Chronic myocardial ischemia contraindication 413844008 DOID:3393




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 11.71 acidic
pKa2 8.15 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
EQ 1MG BASE INTUNIV TAKEDA PHARMS USA N022037 Sept. 2, 2009 RX TABLET, EXTENDED RELEASE ORAL 6811794 July 4, 2022 TREATMENT OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER
EQ 2MG BASE INTUNIV TAKEDA PHARMS USA N022037 Sept. 2, 2009 RX TABLET, EXTENDED RELEASE ORAL 6811794 July 4, 2022 TREATMENT OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER
EQ 3MG BASE INTUNIV TAKEDA PHARMS USA N022037 Sept. 2, 2009 RX TABLET, EXTENDED RELEASE ORAL 6811794 July 4, 2022 TREATMENT OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER
EQ 4MG BASE INTUNIV TAKEDA PHARMS USA N022037 Sept. 2, 2009 RX TABLET, EXTENDED RELEASE ORAL 6811794 July 4, 2022 TREATMENT OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Alpha-2A adrenergic receptor GPCR AGONIST EC50 7.16 WOMBAT-PK DRUG LABEL
5-hydroxytryptamine receptor 2B GPCR Ki 5.88 DRUG MATRIX
5-hydroxytryptamine receptor 2C GPCR Ki 6.12 DRUG MATRIX
Alpha-2B adrenergic receptor GPCR AGONIST EC50 5.93 WOMBAT-PK
5-hydroxytryptamine receptor 2A GPCR Ki 6.07 DRUG MATRIX
Alpha-1D adrenergic receptor GPCR Ki 6.26 DRUG MATRIX
Nischarin Membrane receptor Ki 7.72 CHEMBL
Alpha-2C adrenergic receptor GPCR AGONIST EC50 5.68 WOMBAT-PK
Alpha-1A adrenergic receptor GPCR IC50 5.87 CHEMBL

External reference:

IDSource
4019771 VUID
N0000147862 NUI
D00606 KEGG_DRUG
29110-48-3 SECONDARY_CAS_RN
4019438 VANDF
4019771 VANDF
C0079466 UMLSCUI
CHEBI:5558 CHEBI
CHEMBL862 ChEMBL_ID
DB01018 DRUGBANK_ID
CHEMBL1200494 ChEMBL_ID
D016316 MESH_DESCRIPTOR_UI
3519 PUBCHEM_CID
522 IUPHAR_LIGAND_ID
3999 INN_ID
30OMY4G3MK UNII
203142 RXNORM
4809 MMSL
521 MMSL
6549 MMSL
d00717 MMSL
000650 NDDF
004497 NDDF
108553003 SNOMEDCT_US
108554009 SNOMEDCT_US
372507007 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Guanfacine HUMAN PRESCRIPTION DRUG LABEL 1 0093-5960 TABLET, EXTENDED RELEASE 1 mg ORAL ANDA 28 sections
Guanfacine HUMAN PRESCRIPTION DRUG LABEL 1 0093-5961 TABLET, EXTENDED RELEASE 2 mg ORAL ANDA 28 sections
Guanfacine HUMAN PRESCRIPTION DRUG LABEL 1 0093-5963 TABLET, EXTENDED RELEASE 3 mg ORAL ANDA 28 sections
Guanfacine HUMAN PRESCRIPTION DRUG LABEL 1 0093-5964 TABLET, EXTENDED RELEASE 4 mg ORAL ANDA 28 sections
guanfacine HUMAN PRESCRIPTION DRUG LABEL 1 0228-2850 TABLET, EXTENDED RELEASE 1 mg ORAL ANDA 28 sections
guanfacine HUMAN PRESCRIPTION DRUG LABEL 1 0228-2851 TABLET, EXTENDED RELEASE 2 mg ORAL ANDA 28 sections
guanfacine HUMAN PRESCRIPTION DRUG LABEL 1 0228-2853 TABLET, EXTENDED RELEASE 3 mg ORAL ANDA 28 sections
guanfacine HUMAN PRESCRIPTION DRUG LABEL 1 0228-2855 TABLET, EXTENDED RELEASE 4 mg ORAL ANDA 28 sections
Guanfacine HUMAN PRESCRIPTION DRUG LABEL 1 0591-0444 TABLET 1 mg ORAL ANDA 24 sections
Guanfacine HUMAN PRESCRIPTION DRUG LABEL 1 0591-0453 TABLET 2 mg ORAL ANDA 24 sections
Guanfacine HUMAN PRESCRIPTION DRUG LABEL 1 0904-7140 TABLET 1 mg ORAL ANDA 24 sections
Guanfacine HUMAN PRESCRIPTION DRUG LABEL 1 16714-190 TABLET, EXTENDED RELEASE 1 mg ORAL ANDA 28 sections
Guanfacine HUMAN PRESCRIPTION DRUG LABEL 1 16714-191 TABLET, EXTENDED RELEASE 2 mg ORAL ANDA 28 sections
Guanfacine HUMAN PRESCRIPTION DRUG LABEL 1 16714-192 TABLET, EXTENDED RELEASE 3 mg ORAL ANDA 28 sections
Guanfacine HUMAN PRESCRIPTION DRUG LABEL 1 16714-193 TABLET, EXTENDED RELEASE 4 mg ORAL ANDA 28 sections
Guanfacine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 17856-0711 TABLET 1 mg ORAL ANDA 13 sections
Guanfacine HUMAN PRESCRIPTION DRUG LABEL 1 24658-730 TABLET 1 mg ORAL ANDA 24 sections
Guanfacine HUMAN PRESCRIPTION DRUG LABEL 1 24658-731 TABLET 2 mg ORAL ANDA 24 sections
Guanfacine Extended-Release HUMAN PRESCRIPTION DRUG LABEL 1 24979-533 TABLET, EXTENDED RELEASE 1 mg ORAL ANDA 27 sections
Guanfacine Extended-Release HUMAN PRESCRIPTION DRUG LABEL 1 24979-534 TABLET, EXTENDED RELEASE 2 mg ORAL ANDA 27 sections
Guanfacine Extended-Release HUMAN PRESCRIPTION DRUG LABEL 1 24979-536 TABLET, EXTENDED RELEASE 3 mg ORAL ANDA 27 sections
Guanfacine Extended-Release HUMAN PRESCRIPTION DRUG LABEL 1 24979-538 TABLET, EXTENDED RELEASE 4 mg ORAL ANDA 27 sections
Guanfacine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 29300-458 TABLET 1 mg ORAL ANDA 21 sections
Guanfacine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 29300-459 TABLET 2 mg ORAL ANDA 21 sections
Guanfacine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 42291-310 TABLET 1 mg ORAL ANDA 20 sections
Guanfacine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 42291-310 TABLET 1 mg ORAL ANDA 20 sections
Guanfacine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 42291-311 TABLET 2 mg ORAL ANDA 20 sections
guanfacine HUMAN PRESCRIPTION DRUG LABEL 1 42291-324 TABLET, EXTENDED RELEASE 1 mg ORAL ANDA 29 sections
guanfacine HUMAN PRESCRIPTION DRUG LABEL 1 42291-325 TABLET, EXTENDED RELEASE 2 mg ORAL ANDA 29 sections
guanfacine HUMAN PRESCRIPTION DRUG LABEL 1 42291-326 TABLET, EXTENDED RELEASE 3 mg ORAL ANDA 29 sections